Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
This new microcast provides a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering the week ended 10 July.
On the menu this time are developments in Alzheimer’s and NASH, coronavirus antivirals, AbbVie Inc.’s Japan business and HIV prophylaxis.
Stories mentioned in this episode:
(Also see "Biogen/Eisai Hit ‘Send’ On High Stakes BLA For Aducanumab In Alzheimer’s Disease" - Scrip, 8 Jul, 2020.)
(Also see "No Read-Through Expected: NASH Field Unfazed By Intercept’s FDA Rejection" - Scrip, 3 Jul, 2020.)
(Also see "Amid Supply Concerns, EU Approves Gilead’s Remdesivir" - Scrip, 3 Jul, 2020.)
(Also see "AbbVie Eyes Japan Oncology Growth As Humira Biosimilar Looms" - Scrip, 2 Jul, 2020.)
(Also see "ViiV Thinks It May Get All-Gender Approval For Cabotegravir For PrEP" - Scrip, 7 Jul, 2020.)